Kallikrein-related peptidase 6 (KLK6) is a serine protease that is aberrantly altered in various types of cancer, but its role in non-melanoma skin cancer has not been investigated. KLK6 is active in epidermis and has been linked to normal skin differentiation. Thus, we investigated whether it could be implicated in skin tumorigenesis in vivo. Carcinogenesis was induced in Klk6 −/− mice by epidermal application of 7,12-dimethylbenz[a]anthracene/12-O-tetradecanoylphorbol 13-acetate (DMBA/TPA), and multistage skin tumor development and progression was monitored closely until squamous cell carcinomas (SCCs) and invasive tumors formed. Klk6 −/− (but also Klk6 +/− ) mice were highly resistant to tumor growth/ development manifested by their highly diminished numbers and delayed onset of tumors compared with wild-type (wt) mice. Histological analyses of the few tumors that developed in Klk6 −/− after prolonged (>1 year) chemical challenge revealed that these were mainly benign papillomas, whereas in wt mice tumors progressed to SCCs. Inflammation was attenuated in Klk6 −/− skin following chronic exposure to TPA, indicated by markedly low expression of proinflammatory cytokines, in direct contrast to wt. Further, in Klk6 −/− mice, the ability of implanted nascent PDVC57 skin cancer cells to form tumors was highly diminished. Our study identified KLK6 as a new tumor-promoting factor of early skin cancer and suggested that KLK6 is an important molecular link in the development of skin inflammation and in tumor-promoting inflammatory processes.
Introduction
Kallikrein-related peptidase 6 (KLK6) was originally identified by differential expression cloning based on its inactivated expression in lung metastases compared with its high overexpression in the primary tumor of a patient with breast cancer (1) . Previously, we showed that the expression of KLK6 is downregulated in breast cancer through promoter hypermethylation. Re-expression of KLK6 at physiological levels (i.e. those secreted by normal mammary cells) in MDA-MB-231 cells suppresses their tumorigenicity both in vitro and in vivo, indicating a potential tumor suppressor function (2) . However, when KLK6 was highly overexpressed (>50-fold), as observed in a small subset of breast cancers, it promoted tumorigenicity (2) . Also, KLK6 is highly expressed in the skin and the nervous system (brain and spinal cord) and is thought to regulate α-synuclein turnover (3, 4) . Transcriptionally, KLK6 is regulated by multiple promoters and various alternatively transcript variants have been identified (5) .
In the skin, KLK6 is strongly induced by glucocorticoids and is implicated in tachyphylaxis (6) . Specifically, it was demonstrated in vivo that KLK6 is responsible for the development of proliferative resistance after chronic use of topical glucocorticoids, but did not affect the induction of skin atrophy (6) . KLK6 is known to cleave desmoglein Ι in vitro and, therefore, was suggested to participate in the epidermal proteolytic web that controls the process of desquamation (7) . Ectopic expression of Klk6 in mouse keratinocytes induces spindle-like morphology and increases proliferation, migration and invasion, and transgenic mice overexpressing Klk6 show increased keratinocyte proliferation and migration associated with increased wound healing rates (8) . KLK6 is one of the most highly upregulated genes on induction of differentiation with vitamin D3 analogs in keratinocytes (9) and in squamous carcinoma cells (10) . KLK6 is absent in melanomas but it is highly expressed in keratinocytes adjacent to benign nevi, primary melanomas and cutaneous metastatic lesions, suggesting a paracrine function during neoplastic transformation and malignant progression, whereas recombinant KLK6 increased melanoma cell migration and invasion (11) . KLK6 displays elevated expression levels in squamous cell carcinomas (SCCs) compared with premalignant lesions and normal skin (8) . However, the molecular pathways implicating KLK6 in non-melanoma skin cancer have not been described. To elucidate the role of KLK6 in skin tumorigenesis, we chemically induced skin tumors in mice and found that Klk6 −/− mice were highly resistant to tumor formation relative to wild-type (wt) mice. Resistance of Klk6-deficient skin to tumorigenesis is associated with reduced TPA-induced inflammation. Our study reveals a new role for KLK6 in the regulation of skin inflammation and early skin tumor development as well as tumor progression.
Materials and methods

Animals
Klk6 −/− mice were generated in collaboration with Dr I.Michael and Prof. A.Nagy (Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada) and were on C57BL6 background. Briefly, the Klk6 coding exons 3 and 4 were replaced with the 'universal docking site' cassette developed by Prof. Nagy group to address the needs of NorCOMM (12) . A schematic diagram of the transgenic cassette and the PCR genotyping strategy were recently published (3). This methodology allows conversion of the original knockout mutation to one that is conditional, restores wt or introduces disease-specific alleles. The targeting vector was generated by bacterial artificial chromosome recombineering and was electroporated into C57BL6 stem cells. The chimeric mice were derived with diploid aggregation, were found to be 100% transmitters and gave birth to Klk6 +/− mice, which were intercrossed to obtain Klk6 −/− mice. These mice are viable, are fertile and have no prominent phenotypic abnormalities. All experiments with mice were performed in the authorized animal house of the National Hellenic Research Foundation. Experiments complied with the Protocol on the protection and welfare of animals, as obliged by the rules of the National Hellenic Research Foundation and the University of Patras, the regulations of the National Bioethics Committee and article 3 of the presidential decree 160/1991 (in line with 86/609/EEC directive) regarding the protection of experimental animals.
Chemical carcinogenesis
Skin tumors were induced chemically by epicutaneous application of 7,12-dimethylbenz[a]anthracene/12-O-tetradecanoylphorbol 13-acetate (DMBA/TPA). Three days before chemical application, 7-to 9-week-old mice were depilated with Veet cream. Each animal received 50 μg of DMBA in 100 μl of acetone on each flank. After 2 days, mice received 100 μl of 2 × 10 -4 M TPA in each flank twice weekly for 32 weeks. Mice were visually inspected for the appearance of papillomas twice a week. Tumors were allowed to grow for a total of 52 weeks to assess tumor progression.
Tumor cells transplantation
PDVC57 cells (kindly provided by Prof. Balmain who generated them) (13) were grown in Dulbecco's modified Eagle's medium supplemented with 10% serum. When 100% confluent, cells were trypsinized and 2 × 10 6 cells were resuspended in 100 µl phosphate-buffered saline and injected subcutaneously into the left and right flanks of 5-to 6-week-old female mice. On injections, tumors were allowed to grow for 7 weeks. During this period, tumor volumes were measured (as soon as the tumor onset was observed) using the formula V = ½ × height × width × length. At the end of the observation period, mice were killed and tumors were excised and photographed.
Real-time quantitative PCR (RT-qPCR)
Total RNAs from mice tissues or cell lines were extracted, reverse transcribed with Superscript II (Invitrogen) and the resulting complimentary DNAs amplified by quantitative PCR as described previously (14) . Normalization was carried out with HPRT gene.
Histology and in situ zymography
Tissues were collected in optimal cutting temperature, Sakura for in situ zymography or in 4% formaldehyde for hematoxylin and eosin and processed as described (14) . For in situ zymography, skin cryosections (5 µm) were rinsed with 2% Tween 20 in phosphate-buffered saline and incubated for 1 h at 37°C with 100 µg/ml BODIPY FL casein or 10 μg/ml BODIPY FL gelatin in 50 mM Tris-HCl, pH 8.0, then rinsed with phosphate-buffered saline, mounted with Mowiol and visualized with a confocal laser-scanning microscope. Data were analyzed using ImageJ.
Tumor DNA mutation screening
Genomic DNA was isolated from tumors with GenElute Mammalian Genomic DNA Kit (Sigma-Aldrich). The region encompassing codon 61 of H-ras was PCR amplified and the PCR products were resolved on agarose gel, purified and subjected to Sanger sequencing. Primers and conditions have been published elsewhere (15) .
Scanning electron microscopy
Scanning electron microscopy was carried out as described previously (14) .
Inflammatory cells
Tumor samples were fixed in neutral buffered formalin and embedded in paraffin blocks. Multiple sections (thickness 3-4 μm) were obtained from each paraffin block and stained with hematoxylin and eosin. The stained sections were reviewed by a pathologist, not only to assess the presence but also to quantify macrophages, polymorphonuclear leukocytes and lymphocytes located in the peritumoral and intratumoral inflammatory infiltrates. As peritumoral was considered the inflammatory infiltrate located outside the tumor up to 1 mm distance. Quantification led to an arbitrary division in five categories according to the quantity of previously mentioned each cell type [None/Very Low (−), Low (−/+), Moderate (+), High (++), and Very High (+++)].
Results
Klk6
−/− mice are resistant to skin tumorigenesis Klk6 −/− mice do not have apparent abnormalities and they thrive and have a normal life span. Their skin microstructure appears similar to wt and the elimination of Klk6 does not affect the overall epidermal proteolytic levels (Figure 1a and b) . Further, no abnormalities in whisker architecture were found (Figure 1c ), although previously it was reported that Klk6 is expressed in the hair follicles and could be implicated in the development of hair morphology (16) . We found that the epidermis of Klk6 −/− mice is hypoproliferative as also suggested (6) and display normal differentiation patterns (data not shown).
We subjected Klk6 −/− , Klk6 +/− and wt mice to chemically induced tumorigenesis with DMBA/TPA. It should be noted that Klk6 +/− mice display approximately five times lower Klk6 expression in the skin when compared with wt ( Figure 1d 
Klk6 deficiency inhibits tumor progression
We histologically analyzed chemically induced skin tumors to assess the potential role of Klk6 in tumor progression. Representative images of tumor sections stained with hematoxylin and eosin are shown in Figure 2c . Most of the tumors grown in Klk6 −/− and Klk6 +/− mice were papillomas, whereas tumors grown in wt mice have progressed to SCCs (Figure 3a) . Because the molecular events occurring at the time of initiation influence the probability with which papillomas progress to malignancy (17), our previously described data on H-ras mutation status could indeed explain why tumors raised in wt mice progress to SCCs more frequently than in other genotypes. Most of the tumors derived from wt mice had increased numbers of inflammatory cell infiltrates (Figure 3b and c) . Specifically, tumors grown in wt mice showed significantly increased numbers of infiltrating macrophages and polymorphonuclear cells compared with those grown in Klk6 −/− and Klk6 +/− mice. Further, tumors derived from wt mice displayed higher numbers of infiltrating lymphocytes.
Ablation of KLK6 restricts growth of nascent tumor cells
To explore the importance of Klk6 to control tumor growth, we challenged wt, Klk6 +/− and Klk6 −/− mice with subcutaneous transplantation of PDVC57 mouse skin squamous carcinoma cells (characterized by two H-ras mutant alleles and one H-ras wt allele and a mutation in p53) (18) . These cells express increased Klk6 messenger RNA levels by approximately 2-fold compared with immortalized mouse keratinocytes ( Figure 4a ). As shown in Figure 4 and 
Attenuated skin inflammation in Klk6-deficient skin
Because chemical carcinogenesis is a process strongly dependent on inflammation (19), we hypothesized that the resistance to tumor formation observed in Klk6 −/− could be related to resistance in the inflammatory reaction induced by TPA. For this, we analyzed chronic inflamed skin from Klk6 −/− and wt animals, treated with TPA twice a week for 32 weeks for the expression of inflammatory cytokines. As shown in Figure 5, 
Klk6
−/− skin compared with wt. For most of the cytokines, their levels after TPA application in Klk6 −/− skin were almost at the same levels without TPA. Further, we analyzed the expression of KLK enzymes (Klk5, Klk6, Klk7, Klk8 and Klk14) in the epidermis before and after TPA. Klk5, Klk6, Klk7, Klk8 and Klk14 were highly induced in wt mouse skin (Supplementary Figure 3, (20) . Deletion of either Klk5 (14) or Klk7 in Spink5 −/− (21) mice suppresses inflammatory cytokines. In addition, as shown in Figure 2c , the thickness of the epidermis (hyperplasia) is significantly larger in , that is consistent with increased inflammation. In conclusion, Klk6 deficiency highly suppresses the TPA-induced inflammatory reaction. 
Skin tumors grown in
Discussion
Previously, Klk6 was found upregulated after acute exposure of mouse skin to TPA and after chronic induction of inflammation with TPA (22) . The (patho)physiological significance of this finding, i.e. whether Klk6 is upregulated to promote the inflammatory reaction or as a countermeasure to prevent inflammation, has not been investigated. KLK6 expression has been found upregulated in SCC compared with premalignant lesions that was also higher compared with normal skin (8) . We investigated whether KLK6 is functionally implicated in non-melanoma skin cancer and found that deficiency of Klk6 is associated with remarkable suppression of primary skin tumor formation and malignant progression. Interestingly, during tumor promotion by TPA, inflammation is not efficiently induced in Klk6-deficient epidermis indicated by the low levels of pro-inflammatory cytokines in accordance with substantially reduced epidermal thickening compared with wt. Conclusively, in the absence of Klk6, inflammation is not efficiently induced by TPA and this could provide resistance to tumorigenesis. Moreover, the nascent growth of PDVC57 tumors was markedly inhibited in Klk6-deficient skin revealing that elimination of Klk6 alone compromises skin potential to support the growth of cells with already established malignancy. Multiple studies have shown that KLK6 displays aberrant expression in various types of cancer. We have shown that reexpression of KLK6 at physiological levels in MDA-MB-231 breast cancer cells suppresses their tumorigenicity in vitro and in vivo (2) . On the other hand, KLK6 increases the invasiveness of colon cancer cells (23) . The expression of KLK6 is increased during progression of colon adenoma to carcinoma (24) and higher levels of KLK6 in colorectal carcinoma are a marker of poor prognosis (25) . Upregulation of KLK6 expression in colon carcinoma cells is mediated by mutant K-RAS (26) . Strong KLK6 immunostaining has been observed in the inflammatory cells of colon adenomas, indicating that KLK6 could be related with tumor inflammation (24) . In this context, we found that most tumors derived from wt mice ( Figure 3) showed skin infiltration of inflammatory cells.
A role of KLK6 in driving skin inflammation is further supported by studies on psoriasis. Klk6 is upregulated in imiquimod-induced psoriasis-like model in mice and is required for the development of psoriasiform skin by promoting neutrophil infiltration (27) . Deletion of Klk6 reduced the development of psoriasiform dermatitis (27) . Also, KLK6 is highly increased in the skin of the KC-Tie2 mouse psoriasis model and is increased in lesional psoriatic skin (28) . Patients with psoriasis exhibited increased serum KLK6 levels that correlated with Psoriasis Area and Severity Index score (29) . Taken together with our findings of inefficient induction of inflammation in the absence of Klk6, it could be that KLK6 is a key molecule responsible for the development of skin inflammation in various conditions. Nonetheless, the molecular pathway(s) implicating KLK6 in the inflammatory reaction in skin merit further investigation. These findings indicate that inhibition of KLK6 could provide a way to treat skin disorders associated with increased inflammation. KLK6 is also overexpressed in atopic dermatitis (30) , a rather common skin disease characterized by inflammation. It is possible that a role of KLK6 in inflammation may not be restricted to skin, because reduced levels of inflammatory cytokines were observed in the absence of Klk6 in the experimental autoimmune encephalomyelitis model of multiple sclerosis (31) .
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